What does Coave Therapeutics do?

Coave Therapeutics is a clinical-stage biotechnology company based in Paris, France. The company specializes in targeted gene therapies using its proprietary ALIGATER™ platform, which enhances the precision and safety of treatments for rare ocular, central nervous system, neuromuscular, and neurodegenerative diseases. Coave develops first-in-class ligand-conjugated AAV vectors that are designed for highly specific tissue delivery, including innovative approaches for retinal vascular diseases. The company's lead program, CoTx-101, is advancing toward clinical development as a durable treatment for retinal diseases, aiming to reduce the need for frequent injections while providing sustained vision improvements. Coave has a broader pipeline of preclinical assets targeting various conditions and plans to advance two candidates to clinical studies in 2026. With significant funding from notable investors, Coave Therapeutics is focused on translating innovative science into effective therapies through its expertise in AAV vector engineering and therapeutic development.